Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265291 · ClinicalTrials.gov registry record · Phase 2
Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group
A Phase 2 study, sponsored by National Institute of General Medical Sciences (NIGMS).
- Completed
- Registry status
- Phase 2
- Development phase
- 700
- Enrollment target
NCT00265291 is a Phase 2 study that has completed, run by National Institute of General Medical Sciences (NIGMS). The registered enrollment target is 700 participants.
The verdict
NCT00265291, a Phase 2 study, has completed, sponsored by National Institute of General Medical Sciences (NIGMS).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 700 participants
- Enrollment target
Study Summary
Our goal is to study pharmacogenetics in Mexican-Americans, using depression treatments as a proof of the concept that pharmacogenetic approaches can be used to optimize treatment strategies for common and complex disorders in this population.
Interventions
- DRUG fluoxetine or desipramine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 1999-11 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00265291
The ClinicalTrials.gov registry entry for NCT00265291 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of General Medical Sciences (NIGMS), which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which fluoxetine or desipramine is the first listed.
NCT00265291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00265291 about?
NCT00265291 is a clinical study titled "Antidepressant Treatment of Mexican-Americans: UCLA Pharmacogenetics and Pharmacogenomics Research Group". Our goal is to study pharmacogenetics in Mexican-Americans, using depression treatments as a proof of the concept that pharmacogenetic approaches can be used to optimize treatment strategies for common and complex disorders in this population.
What is the current status of trial NCT00265291?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 700 participants. The study started on 1999-11. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00265291?
The interventions under investigation include: fluoxetine or desipramine (DRUG).
Who is sponsoring clinical trial NCT00265291?
This trial is sponsored by National Institute of General Medical Sciences (NIGMS), which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.